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Abstract
This article reviews the antitumor and anti-HIV activities of naturally occurring triterpenoids,
including the lupane, ursane, oleanane, lanostane, dammarane, and miscellaneous scaffolds.
Structure–activity relationships of selected natural compounds and their synthetic derivatives are
also discussed.
1 Introduction
Natural products are an excellent reservoir of biologically active compounds. For centuries,
extracts from natural products have been a main source of folk medicines, and even today,
many cultures still employ them directly for medicinal purposes. Among the classes of
identified natural products, triterpenoids, one of the largest families, have been studied
intensively for their diverse structures and variety of biological activities. As a continued
study of naturally occurring drug candidates, this review describes the research progress
over the last three years (2006–2008) on triterpenoids possessing cytotoxic or anti-HIV
activity, with focus on the occurrence, biological activities, and structure–activity
relationships of selected compounds and their synthetic derivatives.
2 Potential antitumor effects of triterpenoids
2.1 The lupane group
Betulinic acid (1) is a naturally occurring pentacyclic triterpene belonging to the lupane
family. It is present in many terrestrial plant species, e.g., Ancistrocladus heyneanus,
Diospyros leucomelas, Syzygium formosanum, Tetracera boliviana, Tryphyllum peltatum,
and Ziziphus vulgaris.1–3 Compound 1 can also be obtained in quantity from the bark of the
London plane tree, Platanus acerifolia.4,5 Table 1 lists other plant sources of 1 reported since
2006.
Trumbull and co-workers6 identified the inhibitory activities of compound 1 against tumor
promotion in 1976. Later, its action was identified as a melanoma-specific cytotoxicity
mediated by the induction of apoptosis.7 The cytotoxicity as well as mechanism of action of
1 have been reviewed.8–11 Although it was initially identified as a melanoma-specific
cytotoxic agent, in more recent studies, 1 showed antiproliferative activity against MCF-7
cells (GI50: 0.27 µM),12 as well as neuroblastoma (SKNAS), rhabdomyosarcoma-
medulloblastoma (TE671), breast carcinoma (T47D), lung carcinoma (A549), colon
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adenocarcinoma (HT-29), multiple myeloma (RPMI8226), cervical carcinoma (HPCC), and
glioblastoma multiforme (HPGBM) cell lines (IC50: 2.4–4.5 µM).13 It also showed broad-
spectrum cytotoxicity towards lung, colorectal, breast, prostate, and cervical cancer cell
lines,14 as well as drug-resistant colon adenocarcinoma cell lines (SNU-C5/WT, SNU-
C5/5FU-R, and SNU-C5/OXT-R).15
Compound 1 induces apoptosis11,16 through the mitochondrial pathway.15,17,18 A typical
decrease in bcl-2 and cyclin D1 gene expression and increase in bax gene expression was
observed in several cancer cell lines treated with 1,13,19 which agreed with prior literature.18
Subsequent studies on its anticancer mechanism revealed that 1 is a potent activator of the
chymotrypsin-like activity of the proteasome.20 In addition, 1 decreases expression of
vascular endothelial growth factor (VEGF) and the antiapoptotic protein survivin in prostate
cancer cells (LNCaP) by activating selective proteasome-dependent degradation of the
transcription factor’s specificity proteins.21 Compound 1 also inhibits NF-κB expression in
androgen-refractory human prostate cancer cells (PC-3), which exhibit high constitutive NF-
κB expression.19
Furthermore, although 1 reportedly is an inhibitor of human topoisomerases (topo) I and
IIα,22,23 it does not show synergistic effects with other topo-I inhibitors. In contrast, 1
inhibited the formation of topo-I DNA cleavable complexes (apoptotic mediatora) induced
by camptothecin, staurosporine, and etoposide in prostate cancer cells.24 This study also
indicated that the tumor death mediated by 1 can be counteracted by the mitogen-activated
protein kinase 1 (MAPK1) inhibitor U0126 in melanoma cells.25
Structure–activity relationship (SAR) studies of 1 have led to the preparation of numerous
C-3 hydroxyl, C-20 double bond, C-28 carboxylic acid, and miscellaneous modified
analogues. In most cases, C-3 modification led to altered cytotoxic potency and selectivity,
while reduction of the C-20–C-29 double bond and replacement of the C-28 carboxyl group
with ester and amide side chains generally gave derivatives inactive against cancer cell
lines.9 Recent approaches revealed similar results. Compound 2, the C-3 epimer of 1,
demonstrated decreased cytotoxicity when compared with 1.56 Betulinic C-3 esters 3 and 4
exhibited better activity against KB cells.57 3-O-Glycosidated derivatives 5 and 6 were 8- to
12-fold more potent than 1 (IC50: 2.6–3.9 µM) against cancer cells and showed better
selectivity compared with healthy cells (IC50: 31 µM).58 The C-28 monosaccharide
derivatives (7) showed slightly increased cytotoxicity, whereas trisaccharide analogues (8)
were inactive.59 In anti-HIV studies, adding a C-28 side chain was a successful structure
modification strategy; however, the resulting potent anti-HIV lead 9 (IC9564) lost the ability
to activate chymotrypsin-proteasomal activity compared with 1.20
2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) is a promising anticancer
synthetic oleanolic acid analogue (see Section 2.2), and this same CDDO modification
concept (incorporating a 2-substituted-1-en-3-one A-ring in the triterpenoid skeleton) was
also applied to 1. The resulting A-ring-modified 2-substituted-1-en-3-one derivatives (10–
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14) showed enhanced cytotoxic or cytostatic activity against pancreatic (Panc-28), colon
(SW480), leukemia (U937), and myeloma (RPMI 8226) cancer cell lines.60,61 Compared
with 10–12, analogues 13 and 14, which have a methylcarboxy rather than cyano group at
C-2, showed increased potency in an apoptosis assay.61 Expanding the ring system by
incorporating an indole or pyrazine ring at C-2 and C-3 afforded heterocyclic analogues
(15–19), which were more potent than the parent compound, 1, against pancreatic
(MIAPaCa2), ovarian (PA-1), and other (SW620, A549, HT-29, K-562, K-562-tax, and -b2–
4) cancer cell lines.62,63 Non-typical synthetic approaches to C-30 and E-ring modifications
led to the oxo-lupane analogues 20–23, which also showed enhanced cytotoxicity against
CEM cells (IC50: 5–7 µM).64
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Compound 1 has also been evaluated for additional biological activities. It reduces the
activity of cholesterol acyltransferase (ACAT-1 and ACAT-2)48 and the formation of
triglyceride (TG) by inhibiting diacylglycerol acyltransferase in human HepG2 cells.31
When studied for cardiovascular activity, 1 demonstrated up-regulation of eNOS and down-
regulation of NADPHoxidase in human endothelial cells.65 The proinflammatory effect of 1
was proved by blocking the interaction of C1q with antibodies in the classical pathway.66
Moreover, 1 displayed anti-inflammatory activity through the suppression of both NO and
PGE2 generation by macrophages, with IC50 values of 0.7 and 0.6 µM, respectively.67
Compound 1 is also a competitive inhibitor of the protease (3CL) of SARS-CoV, a highly
virulent coronavirus, with a Ki value of 8.2 µM.68 In other experiments, 1 and various C-3
modified analogues showed antimicrobial activity, with inhibitory effects toward
Mycobacterium tuberculosis (MIC: 10–109 µM),30,69 Trichophyton soudanense (MIC: 54.8
µM), and T. mentagrophytes (MIC: 27.4 µM).70 Compound 1 also inhibited the invasion of
Porphyromomas falciparum into erythrocytes, with IC50 values of 13.8 µM,71 and blocked
the binding effects of heat-labile entero-toxin (LT) of E. coli in intestinal epithelial cells,
resulting in the suppression of LT-induced diarrhea.72
Lupeol (24), a very common lupane-triterpene widely distributed in the plant kingdom,
occurs across a multitude of taxonomically diverse genera and geographical areas. In a
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survey of the Chemical Abstracts database, more than 100 literature references during the
period 2006 to 2008 reported the occurrence of lupeol. A recently published review
described the chemopreventive prospects, molecular target, and mechanism of action of
24.73 In an earlier investigation of apoptotic induction and cell arrest in various cancer cells,
further molecular-level phenomena involving MAPK, PI3K/Akt, death receptor, and NF-κB
signaling pathways were also revealed.73 The following in vitro and in vivo studies showed
similar results; 24 inhibited the growth of LNCaP cells (IC50: 75 µM) and significantly
reduced testosterone-induced prostate changes in mice by a factor of 1.4.74 Compound 24
arrested the cell cycle at the G(1)-S phase in PC-3 cells75 or the G2/M phase in 451Lu cells
and 451Lu xenografts in nude mice.76 In addition, 24 caused induction of capase-3, and
elevation of the Bcl-2/Bax ratio in LNCaP, PC-3 and 451Lu cells were observed, which are
characteristics of mitochondria-mediated apoptosis.74–76 Interestingly, pre-treatment or post-
treatment with 24 at a dose of 200 mg/mouse showed 56% and 43% preventive effects,
respectively, against DMBA-induced DNA breakage.77
Betulin (25), a C-28 hydroxylated lupane commonly isolated together with 1, generally
showed lower activity in cytotoxic assays than 1.12,59,62,78,79 However, exceptions were
found against A-549, B16-F1, DLD-1, and WS1 cell lines.58 In an SAR study of glycoside
derivatives, glycosidation at C-3 or C-28 of 25 gave 26 and 27, which showed slightly
enhanced cytotoxic activity.59 In other literature reports, derivatives 28 and 29 with C-3 or
C-28 monosaccharide units, respectively, lost cytotoxicity.58 In contrast, the 3-O-
glycosylated derivative of lupeol (30) showed 7–12-fold improved cytotoxicity.58
28-Hydroxy-3-oxo-lup-20(29)-en-30-al (31), obtained from the stems of Microtropis
fokienensis and Perrottetia arisanensis, showed cytotoxic effects toward Hep3B, MCF7,
Ca9–22, and HL60 cell lines (IC50: 1.4–4.7 µM).56 The acetyl ester 32 isolated from
Boswellia carteri was cytotoxic against IMR-32 (IC50: 4.1 µM) and SK-N-SH (IC50: 4.7
µM) cell lines, while its free acid analogue 33 was less potent (IC50: >30.9 µM).80 Betulonic
acid (34) from Betula platyphylla showed cytotoxic effects against KB (IC50: 2.3 µM) and
KB-C2 (IC50: 3.8 µM) cell lines.81
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2.2 The ursane and oleanane groups
The gum resin of genus Boswellia (olibanum or frankincense) has been used traditionally in
Asia and Africa as a folk medicine for the treatment of arthritis and inflammatory
disorders.82 The main active components of the resin are boswellic acids (BAs, 35–40),
which are pentacyclic triterpene carboxylic acids isolated from various Boswellia species
(Burseraceae), including B. carterii, B. frereana, B. papyrifera, B. sacra, and B. serrata.83,84
Chemically, BAs can differ in the positions of the two methyl groups on ring-E; β-BAs (35–
38) have 19,20-dimethyl substitution, while α-BAs (39–40) have 20,20-dimethyl
substitution, classified as the ursane and oleanane groups of triterpenes, respectively.
The relative potency of BAs, proposed mechanisms of action, and molecular targets,
including non-redox-type 5-lipoxygenase (5-LOX), platelet 12-lipoxygenase (p12-LO),
human leukocytes elastase (HLE), cytochrome P450 enzymes (CYP 2C8/2C9/3A4),
topoisomerases I and IIa, and NF-κB kinase (IKK α/b), have been reviewed.83,85 An
inhibitory effect on cycloxygenase-1 (COX-1) by 38 was also identified.86 These targets are
indicative of the anti-inflammatory (5-LOX, p12-LO, HLE, and COX-1) and anticancer
(topo I/IIa and IKK α/β) activities of the BAs.
Fig. 1 summarizes the signal transduction scheme of 38-induced apoptosis. Although the
effector caspases and other markers have been identified, the primary molecular targets as
well as the precise role of mitochondria are still unclear. For details, see the review by
Poeckel et al.83
Compound 38, which is commonly known as AKBA (3-O-acetyl-11-keto-β-boswellic acid),
has been the most well explored BA. A recent discovery revealed that 38 showed moderate
to low toxicity against human skin-derived normal cell lines.87 However, 38 induced
apoptosis in PC-3 and LNCaP cells through a death receptor (DR-5)-mediated pathway,
which is a signal transduction cascade involving the activation of capase-8 and capase-3 in
apoptosis.88 The inhibitory effect of 38 was significant in comparison with those of
indomethacin and cyclophosphamide against bFGF-induced angiogenesis using an in vivo
matrigel plug assay.89 Two C-3 acetylated BA derivatives, 36 and 40, showed almost
comparable activity with cisplatin against neuroblastoma (NB-39 and SK-N-SH) cell
lines.80 Compound 40 triggered apoptosis by activation of caspase-3 and induction of DNA
fragmentation in PC-3 cells and PC-3 xenotransplants in chick chorioallantoic membrane.90
Compound 36 showed similar inhibitory effects to those of β-carotene, reported as 380 and
397 molar ratios, respectively, to 32 pM TPA used as inhibitor, in the TPA-mediated EBV-
EA activation assay.80 In several anti-inflammatory studies, treatment with BAs from B.
serrata diminished chemical- or stress-induced edema, arthritis, and gastric ulcer, with
moderate to low activity.91,92 Compound 38 demonstrated a synergistic effect in
combination with indomethacin on kainic acid-induced excitotoxicity and oxidative damage
in vitro,87,93 and with glucosamine for the treatment of murine edema and arthritis.94
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In anti-inflammatory and other assays, β-BAs generally show greater potency than α-BAs.
In contrast, 3-O-acetyl-α-boswellic acid (AαBA, 40) was the most potent analogue (IC50: 1–
3 µM) compared with β-derivatives against purified topo I.83 The cytotoxic SAR of BAs has
seldom been addressed, but in recent studies, 40 showed higher cytotoxic activity than 39,
indicating the importance of a C-3 acetyl group for optimal potency of α-BAs.80
Furthermore, 4-amino β-BA analogues (41–43) displayed enhanced cytotoxicity compared
with the corresponding β-BAs possessing a 4-carboxylic acid, while C-3 β-epimers of these
amino analogues (44) did not show improved activity.95 A CDDO-like (see Section 2.2)
analogue (45) showed enhanced activity against A-549, A-431, HL-60, MCF-7, T47D, and
HT1080 cell lines, with sub-micromolar EC50 values (EC50: 0.10–0.59 µM).96
Ursolic acid (3β-hydroxy-urs-12-en-28-oic acid (46) is a prevalent pentacyclic triterpenoid
carboxylic acid. It has been found in various plants in both aglycone and glycoside forms,
and traditional uses of plants containing 46 in folk medicine are abundant. Modern studies
have shown that 46 possesses many biological activities, such as anti-oxidative, anti-
inflammatory, antitumor, and hepato-protective activity. The diverse inflammatory effects of
46 were reviewed by Ikeda et al. in 2008.97 This review also summarized the inhibitory
activity of 46 on cancer cells, which may be due to suppression of inhibitors of the NF-κB
pathway and p65 phosphorylation, thereby causing down-regulation of the expression of
downstream oncogenes. Compound 46 may also reduce skin tumor formation by inhibiting
the binding of carcinogen to epidermal DNA or cell membrane. Furthermore, 46 induces cell
differentiation and apoptosis in certain cancer cell lines. For details, see the review by Ikeda
et al.97
Current work has provided more evidence on the bioactivity of 46. Inhibitory effects were
observed on both the PI3K-Akt and MAPK P44/42 pathways, which are associated with cell
apoptosis in endometrial cancer cell lines (SNG-II and HEC108).98 Compound 46 exhibited
chemopreventive effects during the cancer initiation phase of an in vivo inhibitory assay of
aberrant crypt foci (ACF), which are putative precursors of colon cancer, and increased
neutral sphingomyelinase (N-SMase) activity.99 Compound 46 also inhibited endogenous
reverse transcriptase (RT), an enzyme involved in the control of cell proliferation and
differentiation, in melanoma (A375) and anaplastic carcinoma (ARO) cell lines. Down-
regulation of the expression of two cancer-related genes, c-myc and cyclin-D1, in A375 and/
or ARO cells was stimulated by 46.100 In contrast, 46 reduced the amount of L1210 cell
growth inhibition induced by doxorubicin. The result might be due to scavenging of ROS
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involved in the apoptotic processes induced by doxorubicin.101 A similar inhibitory pattern
was observed on H2O2-induced DNA breakage in HL-60 cell lines treated with 46.102
In other SAR studies, compounds with an acetyl moiety on the C-3 hydroxy group (47)
showed greater potency than those with a free hydroxyl.103 In addition, the CDDO
modification strategy was applied. The C-2 cyano or trifluoromethyl derivatives of 1-en-3-
one-ursolic acid (48 and 49) showed better activity than C-2 iodo- and non-substituted
analogues (50 and 51) in anti-proliferation assays using KU7, 253JB-V, Panc-1, and
Panc-28 cancer cell lines (IC50: 0.17–1.13 µM).104
The bioactivities of other naturally occurring ursane-triterpenes have also been reported.
Topical application of asiatic acid (52) resulted in a significant reduction in skin tumor
formation induced by TPA, and TPA-induced [3H]thymidine incorporation was lessened.
Concurrently, 52 inhibited the TPA-induced generation of NO and expression of iNOS and
COX-2, which are important factors in tumor promotion.105 In addition, 52 induced
apoptosis in PPC-1 and U-87MG cancer cells. The apoptotic phenomena included early
activation of caspase-2, −3, and −8 in PPC-1 cells111 and caspase-9 and −3 in U-87MG
cells.112 Intracellular release of Ca2+ was observed in both cell lines, and U-87MG cell
death was alleviated by BAPTA/AM, an intracellular Ca2+ inhibitor. These results implied
that the cell death is attributable to Ca2+-mediated necrotic apoptosis.106
Two new ursane-type triterpenes, microfokienoxane C (53) and 3β,28-dihydroxy-11α-
methoxyurs-12-ene (54), were isolated from the leaves of Microtropis fokienensis.
Compound 53 was cytotoxic against HepG2 and Hep3B cancer cell lines, with IC50 values
of 8.1 and 9.5 µM, respectively. Compound 54 showed activity against the HepG2 cell line,
with an IC50 value of 9.2 µM.107
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Glycyrrhizin (55) and its aglycone, glycyrrhetic acid (56, GA), are abundant constituents of
licorice (most familiarly the species Glycyrrhiza glabra). The aglycone 56 exists as 18α- and
18b-isomers, and 18b-GA was more effective than 18α-GA in inhibiting the mutagenicity
induced by various mutagens.108 A recent review on the pharmacological effects of
Glycyrrhiza sp. described the broad-spectrum of bioactivities of 55 and 56, including anti-
inflammatory, antiviral, hepatoprotective, antitumor, and immunomodulatory.109 For details
about prior studies on antitumor activities of 55 and 56, see the reviews by Wang and
Nixon108 and Asl et al.109
Although several studies have found that GA demonstrates cytotoxic or apoptotic activity,
most of the results have shown only moderate or low potency. Thus, investigation has
focused more on the preparation of active derivatives and chemosensitizing activity. Two 56
analogues, 57 and 58, which possess a C-3 alkoxyimino group and a C-29 carboxylic acid or
methyl ester, showed slightly stronger antiproliferative and apoptotic activities than 56. The
GI50 value improved from 63 µM to 19 µM against HL-60 cells. However, the C-29 free
acid (58) is important, because the methyl ester analogue (57) was less potent in the
apoptosis assay.110 The application of 2-cyano-1-ene-3-one (CDDO) modification on GA
was successful, as methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate (59, β-CDODA-
Me) was active against HL-60 cells at a sub-micromolar concentration (EC50: 0.93 µM).96
Another study reported that 59 and the 2-trifluoromethyl derivative (60) were more
cytotoxic against KU7 (IC50: 0.38–1.59 µM), Panc-1 (IC50: 0.82–1.22 µM), Panc-28 (IC50:
1.14–1.80 µM), and 253JB-V cells (IC50: 0.25–0.67 µM) compared to 56. The relative
potencies of 59 and 60 were dependent on cell line.111
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A mechanism study on 59 revealed that its potent antitumor activity may be due to
differential induction of two tumor-suppressor genes, Krüppel-like factor-4 (KLF-4) and
caveolin-1, in colon cancer cells.112 Subsequent pro-apoptotic responses were also induced
through activation of kinases ATF3, NAG-1, and p21 or through kinase-independent
inhibition of AR and PSA, resulting in the growth inhibition of LNCaP cells.113 Compound
56 showed chemosensitizing effects with various clinical oncology drugs; it enhanced the
sensitivity of vinblastine against KB-C2 cells and doxorubicin against KB/MRP cells. In
addition, 56 partly reversed multidrug resistance in P-gp-expressing cells (KB-C2) or
multidrug resistance protein 1 (MRP1)-expressing cells (KB/MRP), by increasing the
intracellular accumulation of the antitumor drugs.114 In an interesting study, chemical
conjugates of 56 and paclitaxel were synthesized. However, although the conjugated
compounds (61) showed better activity than 56, they were still less potent than paclitaxel
itself.115 Based on these findings, it is likely that glycyrrhetic acid analogues elicit antitumor
activity through multiple pathways.
Oleanolic acid (62, OA), a well known triterpene occurring in numerous varieties of plants,
possesses many biological properties, including anti-inflammatory, trypanocidal, anti-HIV,
and cytotoxic activities.116 In 1988, OA was reported to suppress TPA-induced tumor
promotion.117 Synthetic A-ring modified OA analogues with improved cytotoxicity were
pursued, and 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (63, CDDO) as well as its C-28
methyl ester, CDDO-Me (64, RTA402), were designed and synthesized by Honda et al. in
1998. Both of these synthetic derivatives strongly inhibited the production of NO induced by
IFN-γ in mouse macrophages (IC50: 0.4 nM).118 Further derivatization of CDDO to yield
imidazolides (65, CDDO-Im), amides (66 and 67), or a dinitrile (68, Di-CDDO),
significantly increased the anti-NO activity. Among these derivatives, CDDO-Im (65), was
100 times more potent than CDDO, with an IC50 value of 1 pM.119 In addition to the strong
anti-inflammatory activity, CDDO derivatives were reported to exhibit other bioactivities,
including cytoprotection, cancer cell growth inhibition, and apoptosis induction.120
Preliminary studies confirmed that OAs have the potential to become an important new
treatment for multiple forms of cancer, and both 63 and 64 are currently in phase I clinical
trials for the treatment of metastatic or unresectable solid tumors or lymphoma. The
pharmacological effects induced by OA-related derivatives were summarized in very recent
reviews by Liby et al.,120 Sogno et al.121 and Sultana et al.116
Xanifolia-Y (69) was isolated from Xanthoceras sorbifolia, and several hydrolyzed
derivatives (70–72) were prepared. Glycoside 69, which has angeloyl groups on C-21 and
C-22, was more cytotoxic (IC50: 2.63 µM) to OVCAR3 cells than either the non-esterified
glucoside or the di-esterified aglycone (70 and 71, IC50: >120 µM and 14.2 µM,
respectively). Thus, the ester moieties on C-21 and C-22 are required for the cytotoxicity,
while hydrolysis of the trisaccharide slightly lowered activity.122
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Maslinic acid (73), an oleanane triterpene identified from Crataegus oxyacantha in 1953,123
was recently also isolated from apple peel along with the derivatives 74 and 75. All three
compounds were evaluated for antitumor activity, and 74 together with 75 showed minor
antiproliferative effects against HepG2 (EC50: 17.9–20.6 µM), MCF-7 (EC50: 20.9–29.2
µM), and Caco-2 (EC50: 8.9–14.2 µM), while 73 showed an effect only on the Caco-2 cell
line (EC50: 15.4 µM).124 Compound 73 was also isolated quantitatively from olive fruit, but
showed only a weak anti-proliferative effect against the HT-29 cell line (EC50: 101.2 µM)
without any necrotic effects.125 25-Hydroxy-3-oxoolean-12-en-28-oic acid (76, amooranin)
was isolated from the stem bark of Amoora rohituka. It was cytotoxic against the SW620
cell line (IC50: 6.2 µM) and delayed tumor growth rate in SW620 xenografts in nude mice.
Concurrently, a microarray study of 76 showed that it caused down-regulation of VEGF and
JUN genes, which are associated with angiogenesis and antiproliferation of cancer cells,
respectively.126 Capilliposide B (77), an epoxy-oleanane saponin isolated from Lysimachia
capillipes, was cytotoxic against human A-2780 cells, with an IC50 value of 0.08 µM.127 In a
semi-synthetic approach,128,129 analogues were prepared from 77 and screened for
cytotoxicity. However, only the 3-O-β-D-glucopyranoside (78) and 3-O-β-D-
galactopyranoside (79) derivatives showed enhanced antitumor activity (IC50: 30–40
µm).128 Two D:C-friedooleanane-type compounds (multiflorane-type), 80 and 81, isolated
from the stems of Lagenaria siceraria, showed significant cytotoxicity toward the human
SKHEP-1 hepatocellular cancer cell line with IC50 values of 8.0 and 4.6 µm, respectively.130
2.3 The lanostane group
Ganoderic acid D (82) isolated from Ganoderma lucidum was assessed for anti-proliferation
activity and showed an IC50 value of 17.3 µm against human cervical carcinoma cells
(HeLa). Furthermore, the 82-treated HeLa cells were arrested at the G2/ M phase of the cell
cycle with apoptosis. A simultaneous proteomic study led to the identification of 21 genes
regulated by 82, while the 14-3-3 protein-related genes may play an important role for 82-
induced cytotoxicity.131 Ganoderiol F (83) derived from Ganoderma amboinense, was found
to inhibit proliferation of cancer cell lines, including chronic myelogenous leukemia (K562,
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IC50: 4 µm) and hepatocellular carcinoma (HepG2 and Huh7, IC50: 17 µm and 8.5 µm,
respectively). Activation of MAPK/ EKR and up-regulation of CDK inhibitor p16 were
found in early stages of treatment with 83 and were presumed to cause cell-cycle arrest at
the G1 phase and trigger premature senescence of HepG2 cells.132 Dehydrotrametenolic
acid (84), a lanostane triterpene isolated from the sclerotium of Poria cocos, selectively
inhibited H-ras-transformed J82 cells and induced apoptosis through the caspase-3 pathway.
Cells treated with 84 were arrested at the G2/M phase and accumulated at the sub-G1 phase,
with a high GI50 value of 40 µm. Compound 84 also regulated the expression of H-Ras, Akt,
and ERK, which are the downstream proteins of H-Ras signaling pathways.133 In addition, a
subsequent study of the same fungus yielded 12 lanostane triterpenes (85–96), which
showed inhibitory effects in the EBV-EA activation assay in Raji cells. Compounds 90 and
96 also showed inhibitory effects in DMBA- and TPA-mediated in vivo murine skin
tests.134
Impatienside A (97) and bivittoside D (98), two lanostane-type triterpenes containing C-3
hexasaccharide moieties, were isolated from the sea cucumber Holothuria impatiens. The
two glycosides exhibited in vitro cytotoxicity equal or slightly better than those of the
clinical antitumor drug etoposide (VP-16) against seven different human tumor cells,
including colon cancer (HCT-116 and HT-29), lung cancer (A549), hepatoma (HepG2),
prostate cancer (DU145), breast cancer (MCF-7), and nasopharyngeal cancer (KB), with
IC50 values of 0.25–1.9 µm.135
Cucurbitane-type triterpenes, isomers of lanostanes, constitute a group of diverse substances
that are known for their bitterness and toxicity. They were isolated initially from
Cucurbitaceae plants and were later found in other plant families. Besides cytotoxicity and
anticancer activity, cucurbitacins also exhibit other wide ranging in vitro or in vivo
pharmacological effects, such as purgative, anti-inflammatory, and anti-fertility. However,
these compounds have had only very limited usage due to their non-specific toxicity. The
distribution, structure characterization, and bioactivities were reviewed by Chen et al. in
2005.136 More recent studies showed that cucurbitacin B (99) possessed weak inhibitory
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effects on laryngeal squamous cell carcinoma (Hep-2, IC50: 39.06 µm), which may be due to
the inhibition of STAT-3, a transcription activator in cell growth.137 23,24-
Dihydrocucurbitacin B (100), isolated from roots of Trichosanthes kirilowii, inhibited the
proliferation of human breast cancer cells (Bcap37, IC50: 1.5 µm) and arrested the cell cycle
at the G2/M phase. The antiproliferation activity was reduced by the caspase-family inhibitor
Z-VAD-FMK, suggesting a mitochondria-dependent pathway.138 Cucurbitacins D (101) and
J (102) elicited anti-proliferative effects on both hepatocellular carcinoma BEL-7402 cells
(IC50: 1.41 and 1.37 µm, respectively) and malignant melanoma SK-MEL-28 cells (IC50:
1.22 and 1.28 µm, respectively).27
2.4 The dammarane–euphane group
Ginsenosides are a series of compounds comprised of more than 60 triterpenes and related
glycosides isolated from the leaves, stems, berries, and roots of different Panax species.
Recently, ginsenosides from natural resources were evaluated for their antitumor activity.
However, compared to other triterpenes, most ginsenosides showed low to no cytotoxicity
(IC50: >20 µm) against various cancer cell lines.139–144 The anti-angiogenic properties of
20(S)-protopanaxadiol (103) and 20(S)-protopanaxatriol (104) were evaluated in an in vitro
angiogenesis assay using HUVECs, in which the compounds demonstrated strong anti-
proliferative activity (EC50: 2.16–6.64 µm).142 Furthermore, 20(S)-25-
methoxyprotopanaxadiol (105) induced apoptosis and cell cycle arrest in the G1 phase,
inhibited proliferation of T98G, HPAC, A-549, H1299 and PC-3 cell lines (IC50: 5.0, 5.8,
5.7, 4.9, and 5.8 µm, respectively), and was 5- to 15-fold more potent than 104.145,146 In
addition, three semi-synthetic derivatives with a C-20 sugar moiety (106–108) showed
significant cytotoxicity against MCF, SK-MEL-2, and B16 cancer cell lines147 (see Table
2).
25-Methoxyhispidol A (109), a tirucallane triterpene isolated from the fruit of Poncirus
trifoliata, demonstrated a slight antiproliferative effect (IC50: 21.0 µm) against the SKHEP-1
cell line, which was postulated to occur through arrest in the G0/G1 cell cycle and induction
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of apoptosis.148 The dammarane derivative 110 was isolated from the flower spikes of
Betula platyphylla.81,149 Compound 110 inhibited the efflux of rhoda-mine 123 KB-C2
cells, implicating MDR-reversing effects by modulating P-gp.149
Five dichapetalin-type triterpenoids, dichapetalins A (111), I (112), J (113), K (114), and L
(115), were isolated from the stem bark of Dichapetalum gelonioides. Compounds 111–113
showed selective inhibitory activity (IC50: 0.3–0.8 µm) against the SW626 human ovarian
cancer cell line, while 114 and 115 showed broader cytotoxicity against Lu1, LNCaP,
SW626, MCF-7, and HUVEC cell lines (IC50: 1.6–14.2 µm).35 Acutissimatriterpenes A, B,
and E (116–118) were isolated from the aerial parts of Phyllanthus acutissima.150
Compounds 116 and 117 exhibited cytotoxicity only against P-388 tumor cell line, while
compound 118 showed cytotoxicity against P-388, MCF-7, and Lu-a tumor cell lines (IC50:
0.007–7.100 µm). Most impressively, 118 demonstrated remarkable cytotoxicity against
P-388 (IC50: 0.007 µm), and was more potent than ellipticine, the positive control (IC50:
0.813 µm).150 However due to the complex structures and the limited extent of the study,
SAR conclusions could not be readily established for dichapetalin-type triterpenoids.
2.5 Other triterpenoids
Quinonoid triterpenes—Celastrol (119), a quinone methide triterpenoid, was isolated
recently from Celastrus orbiculatus,151 Cheiloclinium cognatum,152 and Maytenus
chuchuhuasca.153 It was already known that celastrol exhibits anti-inflammatory,154,155
antioxidant,155 neuro-protective,156,157 and anti-infective properties, and its strong cytotoxic
effect was reported as early as 1981.158 Very recent studies showed that 119 was cytotoxic
against Panc-1 pancreatic cancer cells (IC50: 3 µm) in vitro, active against Panc-1 xenografts
in vivo in mice, and inhibited tumor metastasis in the RIP1-Tag2 transgenic mouse model of
pancreatic islet carcinoma.159
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Previous investigation on the strong antitumor effect of 119 prompted a series of studies on
its molecular target. It enhanced the cytotoxic effects of TNF, paclitaxel, and doxorubicin, as
well as the TNF-κB pathway and NF-κB-regulated gene products.160 Further
pharmacological study showed that 119 inhibited the activation of NF-κB by blocking the
phosphorylation and degradation of IkB kinase in the upstream NF-κB signal transduction
cascade.151 Both 119 and gedunin (136) were found to inhibit HSP90 function by acting
outside the ATP-binding pocket, which is similar to the action of the existing drugs cisplatin
and novobiocin.159,161,162 A concurrent study revealed that 119 suppressed the activation of
aryl hydrocarbon receptor-dependent gene expression in oral leukoplakia (MSK-Leuk1)
cells, which implicates a chemopreventive effect.163 Investigation of its anti-angiogenesis
effect revealed that 119 suppressed angiogenesis by acting on the VEGF tyrosine kinase
receptors, VEGFR-1 and VEGFR-2, but not VEGF itself.164 Compound 119 also showed
both in vitro and in vivo chymotrypsin-like proteasomal inhibitory activity toward purified
proteasome (20S and 26S proteasome, IC50: 2.5–5 µm) in PC-3 or LNCaP cells, and
inhibited PC-3 xenografted tumors in nude mice.165
Subsequent SAR studies on semi-synthetic analogues of 119 concluded that the quinone
methide moiety is important for cytotoxic activity. Dihydrocelastrol (120) and 6-oxo-
pristimerol (121), derivatives with an aromatized quinone methide moiety, were inactive in
both cytotoxicity166 and anti-tubulin polymerization assays.153 The C-29 free acid present in
119 is not required for its ability to induce apoptosis; C-29 ester or amide derivatives (122)
showed an equal or lower potency in inhibiting the growth of human and mouse melanoma
tumor cells.166 Analogues that lack C-29, such as tingenone (123) and 22β-
hydroxytingenone (124), showed lower activity than 119 in in vitro tubulin polymerization
inhibition and cytotoxicity assays against RPMI8226 cell lines.153
Kuo et al. Page 15













Tetranortriterpenes (limonoids)—Triterpenoids belonging to the limonoid family
occur as glucosides and aglycones in fruits of Rutaceae and Meliaceae plant families. They
show putative antitumor properties, and have been sufficiently reviewed regarding their
distribution,167 biosynthetic pathway,168,169 and bioactivity.170,171 The latest study on the
antiproliferative effects of three limonoids, limonin (125), nomilin (126) and obacunone
(127), confirmed that, as either aglycones (125–127) or glycosides (128–130), these
compounds exert versatile action against neuroblastoma cancer cells (SH-SY5Y). They
induced apoptosis, arrested the cancer cell cycle at the G1 phase, and showed an aneuploidic
effect, which elevated the aneuploid numbers in treated cancer cells compared with
untreated ones. Both aglycones and glucosides were toxic to the cells, but aglycones were
less effective in causing rapid cell death.172
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3α,7α-Dideacetylkhivorin (131) was isolated from Khaya senegalensis, and subsequent
cytotoxic screening showed that it was active against SiHa (IC50: 0.11 µM), MCF-7 (IC50:
0.14 µM), and Caco-2 (IC50: 0.07 µM) cancer cell lines.173 Nimbolide (132), a limonoid
extracted from the flowers of Azadirachta indica (neem tree), exhibited potent cytotoxic
activity against U937 (IC50: 1.24 µM), HL-60 (IC50: 1.12 µM), and THP1 (IC50: 1.42 µM)
cells and antiproliferation activity against B16 (IC50: 1.74 µM) cell lines. In a follow-up
study using the U937 cell line, 132 increased the number of aneuploid cells and the
appearance of annexin V positive cells, implicating the occurrence of cell arrest and
apoptosis, correspondingly.174 Two nimbolide derivatives, 133 and 134, were synthesized
from 132, but showed weak activity in the brine shrimp lethality bioassay, indicating the
importance of the lactone ring.175
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Gedunin (135), a limonoid with antimalarial, insecticidal, and antitumor activities, was
recently isolated from Xylocarpus granatum176 and Cedrela sinensis.177 It exerted weak
antitumor activity against the CaCo-2 cell line, with an IC50 value of 16.83 µM.176
However, 135 and its derivatives 136–140 showed moderate cytotoxicity against P-388
murine leukemia cells, with IC50 values ranging from 6.0–17.1 µM. In the same study, 141–
143 exhibited very weak or no activity (IC50: >116 µM), suggesting that an oxygenated
functionality at the 11α-position is critical.177 Further modification at C-7 on 135 gave two
active analogues with C-7 carbamate (144) and ketone (145) groups. These compounds
demonstrated antiproliferative activity comparable to 135, and acted by modulating heat
shock protein (Hsp90) in MCF-7 and SkBr3 cells.178 Methyl angolensate (146), a natural
tetranortriterpenoid derived from the root callus of Soymida febrifuga,179 possessed low
cytotoxic activity (IC50: 100.0 µM), but did induce apoptosis by triggering the intrinsic
pathway.180
Quassinoids—Quassinoids are bitter constituents and secondary metabolites exclusively
of Simaroubaceous origin. They are regarded biogenetically as degraded triterpenoids.
Quassinoids have diverse bioactivities including antifeedant, insecticidal, herbicidal,
antiparasitic, antimalarial, and antitumor effects.181
As early as the 1970s, reports ascribed a wide range of antitumor activity to bruceantin, a
quassinoid triterpene, which elicited major interest in quassinoids as promising lead drugs.
However, the complex chemical structures of quassinoids have limited their anticancer
potential. For more details, see the review by Vieira et al.181
6α-Tigloyloxychaparrinone (147) was isolated from Ailanthus integrifolia in 1978,182 and
its antitumor activities have been reported.183,184 More recent studies led to the isolation of
147 from A. altissima. It showed inhibitory effects on hypoxia-induced VEGF,
erythropoietin expression, and the activation of HIF-1α, a transcription factor protein that
promotes tumor cell adaptation and survival under hypoxic conditions.185 Brusatol (148)
showed cytotoxic activity against P-388 murine cancer cells, with an IC50 value of 0.012
µM. The A-ring modified compounds 149 and 150 showed reduced activity, indicating that
the C-2 enolic oxygen is essential for activity. The 11-ketone analogue 151 showed even
weaker activity, indicating that a β-hydroxy group at C-11 is also important.186
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Triterpenes from marine sources—Numerous sodwanone triterpenes have been
purified from Axinella species. Among them, sodwanone V (152) inhibited activation of
HIF-1 in T47D (IC50: 15 µM) and PC-3 (IC50: 15 µM) cells. It also showed weak
cytotoxicity against MDA-MB-231 breast tumor cells (IC50: 23 µM). 10,11-
Dihydrosodwanone B (153) showed moderate cytotoxicity against T47D cells (IC50: 22
µM). Four derivatives, 154–157, inhibited hypoxia-induced HIF-1 activation in T47D cells
(IC50: 20–25 µM).187
Two sipholane-type triterpenes, sipholenol A (158) and sipholenone A (159), were isolated
from the marine sponge Callyspongia siphonella. They showed cytotoxic activity against the
MCF-7 breast cancer cell line, with IC50 values of 1.2 and 0.9 µM, respectively. At a dose of
0.026 µM per pellet, 159 also showed anti-angiogenic activity in the chorioallantoic
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membrane (CAM) assay.188 In a chemosensitization study, 158 potentiated the cytotoxicity
of the antitumor drugs colchicine, vinblastine, and paclitaxel against MDR nasopharyngeal
cancer cell lines (KB-C2 and KB-V1), by inhibiting P-gp(ABCB1)-mediated drug efflux.189
Jaspolide B (160), a novel isomalabaricane-type triterpene isolated from marine sponges,
Jaspis spp,190 exhibited cytotoxicity toward hepatoma (Bel-7402, IC50: 29.1 µM; HepG2,
IC50: 29.5 µM) and human promyeloleukemic (HL-60, IC50: 0.78 µM) cell lines.191,192
Subsequent studies showed 160 induces apoptosis and cell cycle arrest in HL-60 at the G2/
M phase191 and in Bel-7402 at the G1 phase.192
3 Anti-HIV effects of triterpenoids
3.1 The lupane group
In 1994, the authors’ Natural Products Research Laboratories first discovered that betulinic
acid (1, BA) showed an inhibitory effect against HIV-1IIIB replication, with an EC50 value
of 1.4 µM.193 Since then, betulinic acid has been used as a pre-eminent molecular scaffold in
the development of triterpene analogues as anti-HIV drugs. Systematic structural
modifications were carried out on the C-3 hydroxyl, A-ring, C-19 isopropenyl group, and
C-28 carboxyl moiety, which led to the discovery of many potent anti-HIV agents (Table
3).194,195
The C-3 hydroxy group can be readily acylated with a wide variety of anhydrides and acid
chlorides. Such modification resulted ultimately in the identification of bevirimat (3-O-3′,3′-
dimethylsuccinyl BA, 161), which displayed a significant anti-HIV EC50 value of 0.35
nM.196 The SAR study also showed that an ester functionality at C-3, an appropriate length
of the C-3 side chain, a terminal carboxylic acid moiety, and dimethyl substitution at the
C-3′ position are critical for the enhanced antiviral potency of 161. Further SAR
demonstrated that, within the 3′-dimethyl moiety, the 3′S-methyl contributed more towards
the activity, because 3′S-monomethylsuccinyl-substituted BA (3′S-MSB, 162) and 161
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showed similar antiviral potency (EC50: 8.7 and 1.3 nM, respectively), while 3′R-MSB
(163) showed much reduced activity (EC50: 0.12 µM).197
Mechanism of action studies revealed that 161 retained its nanomolar antiviral potency
against HIV-1 isolates resistant to reverse transcriptase (RT) and protease (PR) inhibitors.
To define the target of 161 (bevirimat), scientists from Panacos Pharmaceuticals Inc. and the
National Institutes of Health characterized the virus produced by cells treated with the
compound.198 The studies showed that 161 inhibited the processing of the viral Gag
polyprotein at a specific step, the conversion of the capsid precursor p25 to mature capsid
(CA) p24, in a dose-dependent manner.198 The impaired cleavage of p25 to p24 led to the
production of morphologically defective, non-infectious, immature viral particles (Fig. 2).
Therefore, 161 was designated as amaturation inhibitor (MI),a new class in the antiretroviral
family. It is currently in Phase IIb clinical trials and will enter Phase III clinical trials in
2009.
Conversely, C-28 ω-aminoalkanoic acid derivatives of 1 were discovered to function by
blocking the viral entry into the host cells.199,200 Incremental chain lengthening significantly
influenced the anti-HIV potency of the derivatives, while the introduction of a second
aminoalkanoic acid at the end of the C-28 side chain could further modulate the antiviral
potency.195 This research led to the discovery of RPR103611 (164),199 a statine derivative,
which inhibits the infectivity of several HIV-1 strains with EC50 values in the range of 0.05–
2 µM, and 9 (IC9564),201 a stereoisomer of 164, which showed equipotency in the antiviral
testing. A43-D (165) was designed with a slightly simplified C-28 substituent.202 It also
showed similar anti-HIV activity compared to 9 and 164.
A mechanism of action study discovered that C-28-modified BA analogues function at a
post-binding step necessary for virus entry to the host cell. Detailed study found that 9
induced a nonproductive gp120 conformation that is not able to trigger a conformational
rearrangement in gp41 for membrane fusion.203 Evidence also indicated that 9 can target the
V3 loop of gp120, a domain involved in chemokine receptor binding.204 The exact binding
target of triterpene derivatives is still under investigation.
Modification of the C-19 isopropenyl group showed little effect on the anti-HIV activity.
Neither saturation of the 20(29) double bond nor allylic substitution at C-30 through an ether
or thioether linkage influenced the anti-HIV activity of the 1 derivatives significantly.205
Further research demonstrated that the C-30 position serves as a good place to incorporate
water-solubilizing moieties and to increase the hydrophilicity of this compound class.205
Interestingly, as indicated, the anti-HIV-1 targets of triterpene analogues can vary depending
on the side chain modification positions. C-28-modified analogues of 1 are potent HIV entry
inhibitors, while C-3-modified derivatives function by blocking virus maturation. A
combination of these two modifications led to the identification of A12-2 (166), a
bifunctional HIV inhibitor that interferes with both viral entry and maturation.202
Compounds 167 and 168, in which a secondary amine forms the C-28 amide bond, exhibited
significantly increased metabolic stability in pooled human liver microsomes.205
Compounds 166–168 showed very potent anti-HIV activity, which was slightly better than
that of 161. Gerrish et al. synthesized another series of 3,28-disubstituted 1-analogues.206
These compounds contained a dimethylsuccinyl ester side chain at C-3 and variously
substituted benzyl and phenethyl amides at C-28. Several compounds in this series showed
potent anti-HIV activity, and 169 and 170 showed the best pharmacokinetic/
pharmacodynamic (PK/PD) properties.206 Generally, substitutions at the ortho-position of
the benzyl or phenyl ring provided the best activity. The 3,28-dimodified derivatives may
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serve as attractive promising leads to develop a next generation of 1-derived HIV-1
inhibitors as clinical trials candidates.
2β-Carboxyl-3β-hydroxyl-norlupA(1)-20(29)-en-28-oic acid (171), a lupane-like triterpene
with a rearranged five-membered A-ring, was isolated from the thorns of Gleditsia sinensis.
It showed significant anti-HIV activity, with an EC50 value of <0.13 µM.207 The fact that
171 differs from 1 only in the A-ring configuration suggests that A-ring functionalities are
important pharmacophores for the antiviral activity of the lupane-type triterpenes.
A new 2,3-seco-lupane triterpene, 16β-hydroxy-2,3-seco-lup-20(29)-ene-2,3-dioic acid
(172), was obtained during a search for antiviral agents in the stems of Stauntonia
obovatifoliola.208 Compound 172 exhibited good anti-HIV-1 protease activity (EC50: 17.8
µM), compared with the control 62 (EC50: 54.38 µM), a known HIV-1 protease inhibitor.208
This result suggested that a seco A-ring with dual polar moieties may increase the antiviral
protease activity of triterpenes. In a concurrent study, lupane-, 30-noroleanane-, and
oleanane-type triterpenes showed similar anti-HIV protease activity during testing. When
analyzing the structures more carefully, it was discovered that the 16β-OH group is
important to the enhanced antiviral potency of lupane triterpenes, as seen with compounds
172–175.
3.2 The ursane and oleanane groups
The oleanane-type triterpene maslinic acid (73) inhibits the HIV-1 protease. In order to
further explore the antiviral activity, several different α- and ω-amino acids (single,
dipeptide, or tripeptide) were coupled at the C-28 position of 73 by using both solution- and
solid-phase synthetic methods. However, only compounds 176 [with 11-aminoundecanoic
acid (11AUA) at C-28] and 177 (with a C-28 conjugate dipeptide of 11AUA and L-valine)
showed approximately 50% inhibition activity against virus replication at 10 µM. These
derivatives showed no cytotoxicity, although 73 itself displayed both cytotoxic and antiviral
activities.209
Prior research on glycyrrhetic acid (56) and its synthetic derivatives mainly led to negative
results.210,211 The modifications focused on substitutions of the C-3 hydroxy and C-30
carboxylic acid groups. Because the rigid triterpene scaffold determines the relative position
of the functional side chains, the skeleton could be very important to the anti-HIV and other
bioactivities. Therefore, the distance from the hydroxy group to the carboxylic moiety and
the dihedral angles of the D/E rings were predicted using modeling software. The results
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provided a possible explanation for why analogues of 56 showed fewer anti-HIV effects
than analogues of betulinic (1) or moronic acid (181).210,211
A recent paper reported the synthesis and anti-HIV activity of a group of analogues of α-D-
glucosamine-conjugated glycyrrhetic acid (56).212 The glucosamine was linked to the 3β-
hydroxy group through a spacer containing phthalic, maleic, or succinic acid residues.
Although such modifications slightly increased the anti-HIV activity of 56, the antiviral
potency of these derivatives remained only moderate. The most potent analogue 3-O-[3-
(N-2-deoxy-α-D-glucopyranos-2-yl)-carbamoyl]-phthaloyl-11-deoxy-glycyrrhetic acid (178)
had an anti-HIV EC50 value of 2.0 µM.212
The anti-HIV and other biological activities of oleanolic acid (62, OA) and its derivatives
were reviewed by Sultana et al. in 2007.116 Basically, OA was identified as an anti-HIV
principle, because it inhibited HIV-1 replication with an EC50 value of 3.7 µM and a
therapeutic index (TI) of 12.8.213 Modification of OA at the C-3 position led to the
discovery of 3-O-3′,3′-dimethylsuccinyl-OA (179), which had significant antiviral EC50
(0.86 nM) and TI (22 400) values.213 However, due to differences in the screening system,
the reported activity of 62 may vary in different publications.211 The mechanism of action of
179 is similar to that of 161, which functions as a maturation inhibitor and blocks the
cleavage of p25 to p24, resulting in the production of morphologically defective, non-
infectious HIV particles. The SAR of 3-O-acyl OAs with different succinyl or glutaryl
substitution showed similar trends compared with 3-O-acyl BA analogues, suggesting that
the C-3 side chain is a very important pharmacophore, while the triterpene backbone may
serve as a docker allowing the side chains to interact with the targets.
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Previously, the optimal C-3 and C-28 side chains were identified in bi-functional betulinic
acid (BA) analogues. Therefore, to extend the research focus on the replacement of
triterpenoid docker, some 3,28-disubstituted OA derivatives were also prepared.210
Compound 180, an OA derivative with 1,7-dia-minoheptane linked at the C-28 position and
3′,3′-dimethyl-succinyl linked at the C-3 position, showed anti-HIV activity, with an EC50
value of 0.95 µM.210 This activity is lower than the identically substituted BA analogue, 166
(EC50: 0.0026 µM), indicating that BA is a better-fit docker than OA.
Moronic acid (181, MA) was isolated from Brazilian propolis, a herbal medicine used
worldwide. It exhibited significant anti-HIV activity with an EC50 value of 0.2 µM and TI of
186.214 In 2006, the authors’ group reported the discovery of a series of MA derivatives that
exhibited remarkable anti-HIV potency. Compounds 182–184, which contain C-3 3′,3′-
dimethylsuccinyl substitution and different C-28 amide side chains, exhibited potent anti-
HIV activity in H9 lymphocytes with EC50 values of 0.017, 0.0156, and 0.007 µM,
respectively (Table 4).211 These activity results are similar to those of 161 (EC50: 0.007
µM), a drug candidate that is currently in phase IIb anti-AIDS clinical trials. Another 3,28-
disubstituted MA derivative (185) was synthesized and had an antiviral EC50 value of 0.055
µM (Table 4).210 Mechanism of action study revealed that 3,28-disubstituted betulinic acid
or moronic acid analogues exhibit both anti-fusion and anti-maturation activity. Thus, they
were designated as bifunctional triterpenes.208,213 From the SAR, it was discovered that a
longer C-28 side chain (as in 184 and 185) is helpful for enhanced antiviral potency.
Another oleanane-type triterpene, papyriogenin A (186), was isolated from the flowers, pith,
leaves, and fruit of Tetrapanax papyriferus. It showed antiviral activity, with an EC50 value
of less than 1.7 µM in HIV-1IIIB-infected H9 lymphocytes.215
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C-3-modified ursolic acid (UA),211,216 as well as 3- and 28-modified UA analogues (187–
189),210,211 were synthesized and evaluated for anti-HIV activity (Table 5). The C-3-(3′,3′-
dimethylsuccinyl)- and C-3-(3′,3′-dimethylglutaryl)-substituted derivatives of UA (188 and
189) exhibited anti-HIV replication, with EC50 values of 0.08 and 0.68 µM, respectively.211
Compound 187, which was evaluated with a different assay system, also displayed anti-HIV
activity, with an EC50 value of 0.23 µM.210 When the activities of triterpenes with the same
side chain but different scaffolds were compared, it was discovered that, among the
synthesized compounds, the most effective molecular scaffold for anti-HIV activity
remained betulinic acid (166, EC50 value: 0.0026 mM), followed by moronic, ursolic, and
oleanolic acids.210
In addition, some a-aminophosphonates were conjugated to the C-28 of UA.217 However, all
of the resulting analogues showed zero-to-weak anti-HIV entry activity. The best compound
(190) inhibited viral entry by only 20% at a concentration of 0.1 µM.217 This result further
proved the conclusion that a longer C-28 side chain is very important for triterpene-derived
HIV entry inhibitors, with a carbon chain length of 7–10 being optimal.
3.3 The lanostane group
Plants of the genus Schisandra are known to contain dibenzo-cycloctadiene lignans, as well
as lanostane and cycloartane triterpenes. In 2003, Sun’s group began a phytochemical study
of several species of the Schisandra genus collected in the Yunnan province of China, which
led to the discovery of a series of norcycloartane triterpenoids. During 2006–2008, Sun’s
group also identified several nortriterpenoids and bisnortriterpenoids from various species of
Schisandra that possessed weak to moderate anti-HIV-1 activity.218–220
Rubriflordilactones A (191) and B (192) were isolated from the leaves and stems of
Schisandra rubriflora.221 They are highly unsaturated rearranged bisnortriterpenoids that
contain a biosynthetically modified aromatic D-ring. The anti-HIV activity of both
compounds was tested in HIV-1IIIB-infected C8166 cell lines, and their cytotoxicity was
evaluated in C8166 and MT-4 cells. Compound 191 showed only weak antiviral potency;
however, 192 presented moderate anti-HIV activity, with an EC50 of 21.1 µM and TI of
12.39.221
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Rubriflorins A–C (193–195), three highly oxygenated nortriterpenoids, were also isolated
from the leaves and stems Schisandra rubriflora.222 They feature an opened A-ring.
Compounds 193 and 194 exhibited moderate anti-HIV-1 activity, with EC50 values of 17.9
and 29.2 µM, respectively, while 195 showed weak HIV-1 inhibition activity, with an EC50
value of 143.1 µM.222 Rubriflorins D–J (196–202) were found in the same plant shortly after
the discovery of 193–195.223 They also contain an opened A-ring and showed moderate to
weak anti-HIV activity, with EC50 values ranging from 26.4 to 167.0 µM.223
Sphenadilactones A (203) and B (204) were isolated from the leaves and stems of
Schisandra sphenanthera.224 Their structural elucidation was accomplished by extensive
NMR and single-crystal X-ray crystallography. However, an erratum was later published to
correct the stereochemistry of Me-27, which should have an α- rather than β-orientation.225
Compound 203 exhibited very weak anti-HIV-1 activity, with an EC50 of 237.8 µM in
HIV-1IIIB-infected C8166 cells.224 No obvious cytotoxicity was observed when both
compounds were tested against three human tumor cell lines, K562, A549, and HT-29. A
minor nortriterpenoid, sphenadilactone C (205), was also isolated in a subsequent study of
Schisandra sphenanthera.226 It is characterized by the presence of a partial enol structure,
and is the first example of an acetamide-bearing highly oxygenated nortriterpenoid from a
cycloartane. Compound 205 also exhibited very weak antiviral activity against HIV-1IIIB,
with an EC50 of 47.8 mM.226
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Re-investigation of Schisandra sphenanthera resulted in the isolation of sphenalactones A–D
(206–209), which have an unusual 27-carbon skeleton derived from cycloartane, due to the
loss of C-2, C-3, and CH3-28.227 This is the first class in the Schisandra species and the first
case in the cycloartane triterpenoid family in which C-2 and C-3 are degraded in the
molecule. Compounds 208–209 demonstrated weak anti-HIV-1 replication activity, with
EC50 values of 185.1, 153.7, 105.4, and 76.2 µM, respectively.227
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Schintrilactones A (210) and B (211), two new nortriterpenoids with modified five-
membered D-ring and δ-lactone E-ring, were isolated from Schisandra chinensis. Both
compounds have a unique carbon skeleton, with an unstable stereogenic center at C-20. The
two diastereomers slowly interconvert through an enol intermediate. Compounds 210 and
211 demonstrated anti-HIV-1 activity, with EC50 values of 33.9 and 68.2 µM, respectively,
compared with AZT as positive control (EC50: 8.46 µM).228 Nortriterpenoids
schindilactones D–G (212–215) and bisnortriterpenoids wuweizidilactones G (216) and H
(217) were also isolated from the stems and leaves of Schisandra chinensis. However, they
demonstrated only weak antiviral activity, with EC50 values ranging from 32 to 181 µM.229
Wilsonianadilactones A–C (218–220) were isolated from the stems and leaves of Schisandra
wilsoniana, a climbing plant distributed in the Yunnan province of China. All three
compounds showed weak anti-HIV-1 activity, with EC50 values of 38.3, 99.1, and 118.6 µM
in an in vitro antiviral assay.230
Lancifodilactone H (221), a trinorcycloartane triterpenoid with a biosynthetically modified
seven-membered lactone ring, and lancifoic acid A (222), a new A ring-secocycloartane
triterpenoid, were isolated from the stems and leaves of Schisandra lancifolia. They
exhibited moderate anti-HIV activity, with EC50 values of 37.4 and 33.2 µM,
respectively.231
The genus Kadsura belongs to the family Schisandraceae. In an investigation of Kadsura
heteroclita, a new nortriterpenoid, long-ipedlactone J (223), was isolated. When tested in
HIV-1IIIB infected C8166 cells, 223 showed a moderate anti-HIV EC50 of 7.1 µM.232
Four new lanostane triterpenes, colossolactones V, VI, VII,and VIII (224–227), were
isolated from the fruiting bodies of the Vietnamese mushroom Ganoderma colossum.233
With seco A- and E-rings, 224 and 225 differ structurally from previous isolated
colossolactones, which have a seven-membered lactone A-ring and six-membered lactone E-
ring. Compound 226 has a lactone E-ring, but seco A-ring, while compound 227 has both A-
and E-lactone rings. These three new triterpenoids, together with three previously isolated
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compounds, collosolactone E (228), schisanlactone A (229), and colossolactone G (230),
were tested against HIV-1 protease. Compounds 224, 226, 228, and 229 showed anti-
protease activity, with EC50 values of 14.6, 24.7, 15.3, and 10.8 µM, respectively, while
225, 227, and 230 were inactive.233
The presence of a hydroxy group at C-23 (R3) or C-5 (R2) in the tested compounds reduced
the activity (i.e., 227 vs. 228 and 230 vs. 228), suggesting that the hydrophobicity of the
triterpene skeleton is important to the anti-HIV-1 protease inhibition activity. For the A-ring
seco compounds, 224 (with a single double bond at C-8–C-9) exhibited higher activity than
the related 225 with two double bonds at C-7–C-8 and C-9–C-11. The unsaturation pattern
would alter the three-dimensional structures and, consequently, the spatial arrangement of
pharmacophores in the compounds, which have a significant influence on activity. On the
other hand, the presence of the seco or lactone A- and/or E-ring did not significantly
influence the anti-HIV protease activity of the analogues.
Two unusual octanorcucurbitacins, endecaphyllacins A (231) and B (232), were isolated
from the tubers of Hemsleya endecaphylla.234 These two compounds, together with three
known cucurbitane analogues including 99, 100, and cucurbitacin I (233), were evaluated
for their ability to prevent the cytopathic effects of HIV-1 in C8166 cells. Although
compounds 231 and 232 showed only moderate anti-HIV activity (EC50: 88.27 and 33.70
µM), 99, 100, and 233 showed significant potency (EC50: 0.16, 0.23, and 1.36 µM,
respectively) in this assay.234 The high activity of 99, 100, and 233 may be due to the
presence of the C-17 functional side chain. However, because 99 is the first reported
common cucurbitane analogue with potent antiviral activity, repeated evaluation may be
necessary to confirm the compound’s potency. Kuguacins A–E (234–238) were isolated
from roots of Momordica charantia.235 They also belong to the cucurbitacin family.
Compounds 236 and 238 displayed moderate anti-HIV-1 activity (EC50: 19.7 and 59.6 µM;
TI: 23.68 and 7.81, respectively). Although compounds 234 and 235 showed moderate
antiviral activity with EC50 values of 22.8 and 24.9 µM, they were also cytotoxic, resulting
in lower TI values of 7.01 and 3.09, respectively. The cucurbitacin analogues hemslecins A
and B (239 and 240) were discovered as antibacterial drugs from Hemsleya jinfushanensis
some time ago. They have recently been shown to have anti-HIV-1 activity, with EC50
values of 4.0–36.3 µM and TI values of >20 in different assay systems.236 Further
mechanism of action study revealed that they can block the transmission of virus through
cell-to-cell fusion, but cannot inhibit the activities of HIV-1 RT, PR, NCp7 zinc ejection, or
viral replication in chronically infected H9 lymphocytes.236 Thus, it is likely that 239 and
240 function as HIV-1 entry inhibitors.
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3.4 The dammarane and euphane groups
Compounds 116–118, together with acutissimatriterpenes C (241) and D (242), were
isolated from Phyllanthus acutissima.150 The anti-HIV-1 activity of the newly discovered
compounds was tested by using a cell-based antiviral replication assay and HIV-1 reverse
transcriptase (RT) assay. Compounds 118 and 242 exhibited moderate antiviral replication
activity, with EC50 values of <5.8 and 8.3 µM, respectively, while 116, 117, and 241
showed weak anti-HIV activity (106.1–130.9 µM). Interestingly, 116 and 117 inhibited the
RT by 55.5% and 65.9% at the tested concentration (^300 µM), while 241 and 242 showed
only 11.0% and 37.8% inhibition against RT. In comparison, compound 242 did not inhibit
RT, suggesting that RT may not be the compound’s target.150 The anti-HIV-1 activity and
mechanism of action of C-31-secodammarane triterpenoids isolated from Alnus firma were
reviewed by Yu et al.237 Among them, alnustic acid methyl ester (243) exhibited anti-HIV
protease activity, with an EC50 value of 15.8 µM. Other similar compounds showed no
effect against RT or protease.
3.5 Other triterpenes
Two hopane triterpenes, dryopteric acids A (244) and B (245), were isolated from the
rhizome of Dryopteris crassirhizoma (Aspidiaceae), and tested against recombinant HIV-1
protease (PR). Both compounds exhibited moderate anti-HIV protease activity, with EC50
values of 26.5 and 44.5 µM, respectively. In comparison, ursolic acid (46) has an EC50 of
8.9 µM. Acetylation of the C-2 hydroxy group of 244 and 245 yielded compounds 246 and
247, which showed enhanced anti-protease activity compared with the parent compounds.238
These results suggested that the carboxylic group at the C-4β (C-24) position and acetyl
group at the C-2 position could play key roles in the inhibition of HIV-1 protease in this
hopane series of triterpene acids.238
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Triterpenoids are an important group for biologically active natural compounds, particularly
with approximately 300 new triterpenoids identified each year. Since 1985, Connolly and
Hill have regularly reviewed the scientific literature dealing with triterpenoid
characterization from natural resources.239–256 Although numerous triterpenoids possessing
various scaffolds have been reported, only a small portion of them were explored
systematically for their pharmacological activities. Of those so explored, most showed only
marginal potency in preliminary screening. However, this fact does not mean that they
should be eliminated from further investigation. For instance, while betu-linic acid (1)
exhibited only moderate anti-HIV activity, with an EC50 of 1.4 µM, modification of 1
furnished the clinical trial agent, bevirimat (161), soon to be a phase III anti-HIV drug.
Another example is CDDO (63), a promising anticancer candidate in phase I clinical trials,
which was derived from oleanolic acid (62), a weak antitumor compound. Generally
speaking, bioactivity-directed fractionation and isolation (BDFI) is a major approach for
new lead generation, which is then followed by lead optimization based on rational drug
design, synthesis, and bioevaluation, as well as structure–activity relationship (SAR) and
quantitative-SAR (QSAR) studies. Selection of a preclinical candidate also involves rapid,
efficient assays to gather absorption, distribution, metabolism, excretion, and toxicity
(ADMET) data, permitting an effective evaluation of drug candidates in the early stages of
the drug discovery process. Although there are still some concerns, especially regarding
structure complexity and non-specific pharmacological effects of naturally occurring
bioactive triterpenoids, their diversity and uniqueness make them worthy of further pursuit
for the discovery of new drugs.
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Simplified apoptotic signaling scheme and modulation by AKBA (from ref. 83): (+) positive
or upregulatory effects of AKBA; (−) negative or inhibitory effects. IKK is the only target
for which a direct inhibition by AKBA has been postulated. n.e.: no effect.
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Bevirimat (161) targets Gag at the CA-SP1 cleavage site to interfere with the processing of
p25 into mature p24, resulting in the production of morphologically defective, non-
infectious viral particles. (Panacos, XVII international HIV drug resistance workshop,
Spain, 2008).
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Table 1
Sources of betulinic acid (1)


























Leaves and twigs Clematoclethra actinidioides51
Cratoxylum arborescens52
Hulls Prunus dulcis12
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Table 2




MCF-7 0.62 2.69 1.86
SK-MEL-2 1.82 2.19 0.19
B16 7.62 6.66 0.37
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Table 3
Structures and anti-HIV activity of C-3- and/or C-28-modified betulinic acid (1) derivatives 161–170a
No. R1 R2 IC50 (µM)







165 H -NH-(CH2)7-NHCOCH3 0.047202
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Table 4
Structures and anti-HIV activity of moronic acid (181) and its C-3- and C-28- modified derivatives 182–185
No. R1 R2 EC50 (µM)
181 H OH 0.220214
182 DSB 0.017211
183 DSB 0.016211
184 DSB -NH(CH2)10COOH 0.007211
185 DSB -NH(CH2)7NHCOCH3 0.055210
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Table 5
Structures and anti-HIV activity of C-3- and C-28-modified ursolic acid derivatives (187–190)
No. R1 R2 EC50 (µM)
187 DSB -NH(CH2)7NHCOCH3 0.23210
188 DSB OH 0.08211
189 OH 0.68211
190 Ac 0.1 (EC20)217
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